PUBLISHER: The Business Research Company | PRODUCT CODE: 2035912
PUBLISHER: The Business Research Company | PRODUCT CODE: 2035912
Direct-from-blood pathogen detection is a diagnostic method that identifies infectious agents such as bacteria, viruses, or fungi directly from a patient's blood sample without the need for prior culture. It helps to enable rapid, accurate detection of bloodstream infections, sepsis, or other systemic infections, allowing timely treatment decisions and improved patient outcomes. This approach reduces diagnostic delays, lowers the risk of complications, and supports more targeted antimicrobial therapy.
The primary technology types of direct-from-blood pathogen detection include polymerase chain reaction (PCR)-based, next-generation sequencing, immunoassay, mass spectrometry, and other technologies. PCR-based methods amplify and detect pathogen DNA or RNA directly from blood samples for rapid and accurate diagnosis. They are applied to bacterial, viral, fungal, and parasitic pathogens. Applications include sepsis, bloodstream infections, hospital-acquired infections, and others, serving end users such as hospitals, diagnostic laboratories, research institutes, and other sectors.
Tariffs on imported diagnostic reagents, sequencing kits, and laboratory instruments are impacting the direct-from-blood pathogen detection market by increasing costs for PCR kits, NGS platforms, and mass spectrometry equipment. Regions such as North America, Europe, and Asia-Pacific that depend on imported molecular diagnostics tools are most affected. While tariffs raise operational expenses, they also encourage local manufacturing of diagnostic kits, stimulate regional R&D investments, and drive innovation in cost-effective pathogen detection technologies, supporting long-term market resilience.
The direct-from-blood pathogen detection market research report is one of a series of new reports from The Business Research Company that provides direct-from-blood pathogen detection market statistics, including direct-from-blood pathogen detection industry global market size, regional shares, competitors with a direct-from-blood pathogen detection market share, detailed direct-from-blood pathogen detection market segments, market trends and opportunities, and any further data you may need to thrive in the direct-from-blood pathogen detection industry. This direct-from-blood pathogen detection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The direct-from-blood pathogen detection market size has grown rapidly in recent years. It will grow from $1.72 billion in 2025 to $1.93 billion in 2026 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to increasing incidence of bloodstream infections, rising demand for rapid diagnostics, growth of hospital and clinical laboratory infrastructure, technological advances in molecular diagnostics, increasing awareness of antimicrobial resistance.
The direct-from-blood pathogen detection market size is expected to see rapid growth in the next few years. It will grow to $3.09 billion in 2030 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to growing adoption of digital and automated pathogen detection platforms, increasing use of multiplex PCR and targeted sequencing, rising demand for point-of-care rapid diagnostics, expansion of hospital and diagnostic laboratory networks in emerging markets, increasing focus on personalized antimicrobial therapy. Major trends in the forecast period include rising adoption of rapid pcr-based diagnostics, increasing use of next-generation sequencing for pathogen detection, expansion of mass spectrometry applications in clinical labs, growing implementation of immunoassay-based detection systems, rising focus on microfluidic and biosensor technologies.
The increasing prevalence of infectious diseases is expected to drive the expansion of the direct-from-blood pathogen detection market in the coming years. Infectious diseases are illnesses caused by harmful microorganisms that invade and proliferate within the body, with the potential to spread to others. The rise in infectious diseases is linked to urbanization, as higher population density in cities facilitates faster transmission of pathogens through close human contact and shared resources. Direct-from-blood pathogen detection supports the identification of infectious diseases by enabling rapid, sensitive, and precise detection of pathogens directly from blood samples. This approach reduces diagnostic delays, informs timely treatment decisions, and enhances patient outcomes through early intervention and targeted therapy. For instance, in 2023, according to the UK Health Security Agency, a UK-based government agency, the incidence of yeast-related bloodstream infections across England increased by 4% compared to 2022. Therefore, the rising prevalence of infectious diseases is propelling the growth of the direct-from-blood pathogen detection market.
Key companies operating in the direct-from-blood pathogen detection market are focusing on developing innovative solutions such as unbiased shotgun metagenomic pathogen detection assays to enable comprehensive, culture-independent identification of a broad range of pathogens directly from blood samples for faster and more accurate diagnosis of bloodstream infections. An unbiased shotgun metagenomic pathogen detection assay refers to a sequencing-based diagnostic method that examines all genetic material in a sample without prior pathogen targeting to identify known and novel infectious agents in a single analysis. For example, in February 2026, MedGenome Labs Limited, an India-based health tech company, launched MetaSeq, a metagenomic next-generation sequencing (NGS) blood test capable of detecting over 1,400 pathogens, including bacteria, fungi, parasites, and DNA viruses, from a single sample. This culture-free technology bypasses traditional blood culture limitations, delivering results in about five days to enable faster, targeted treatment for bloodstream infections, especially in immunocompromised patients.
In June 2025, bioMerieux SA, a France-based in vitro diagnostics company, acquired Day Zero Diagnostics Inc. for an undisclosed amount. With this acquisition, bioMerieux intends to bolster its capabilities in infectious disease diagnostics by integrating Day Zero Diagnostics' cutting-edge genome sequencing and bioinformatics technologies to speed up pathogen identification and antimicrobial resistance detection, thereby improving clinical decision-making and patient outcomes. Day Zero Diagnostics Inc. is a US-based diagnostics company providing direct-from-blood pathogen detection technologies.
Major companies operating in the direct-from-blood pathogen detection market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Becton, Dickinson Company, Illumina Inc., Charles River Laboratories, Hologic Inc., BIOMERIEUX, Bruker Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Tecan Group Ltd., Fluxergy Inc., Q-linea AB, DNAe Group, Karius Inc., T2 Biosystems Inc., Spectral Platforms Inc., BOA Biomedical, Deepull Diagnostics S.L.
North America was the largest region in the direct-from-blood pathogen detection market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the direct-from-blood pathogen detection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the direct-from-blood pathogen detection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The direct-from-blood pathogen detection market consists of revenues earned by entities by providing services such as rapid pathogen identification, antimicrobial susceptibility testing (AST), whole-genome sequencing analysis, data interpretation and reporting, and outbreak monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The direct-from-blood pathogen detection market also includes sales of nucleic acid extraction reagents, sequencing consumables, blood sample enrichment devices, automated sample preparation instruments, and microfluidic cartridges. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Direct-From-Blood Pathogen Detection Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses direct-from-blood pathogen detection market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for direct-from-blood pathogen detection ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The direct-from-blood pathogen detection market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.